Guangdong Hongjing Optoelectronic Technology Inc.
301479
Longkou Union Chemical
301209
Zhejiang Realsun Chemical
301212
4
NEW JCM GROUP
300157
5
Shenzhen S-king Intelligent Equipment
688328
US Stock MarketDetailed Quotes
FATE Fate Therapeutics
- 1.250
- -0.030-2.34%
Close Apr 28 16:00 ET
- 1.250
- 0.0000.00%
Post 16:20 ET
143.25MMarket Cap-0.76P/E (TTM)
1.310High1.230Low1.14MVolume1.280Open1.280Pre Close1.44MTurnover1.14%Turnover RatioLossP/E (Static)114.60MShares5.92052wk High0.45P/B125.12MFloat Cap0.66152wk Low--Dividend TTM100.10MShs Float121.160Historical High--Div YieldTTM6.25%Amplitude0.661Historical Low1.263Avg Price1Lot Size
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fate Therapeutics Stock Forum
Game-Changing FDA Status: Fate's Off-the-Shelf Lupus Treatment Speeds Toward Approval
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (Sle)
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
Monday, 14th April at 8:00 am
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process
– RMAT review by FDA included initial clinical safety and activity data from ongoing Phase 1 study...
finally
No comment yet